# A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers

> **NCT02109185** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 1307 (actual)

## Conditions studied

- Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.
- **DRUG:** Nasonex® Nasal Spray, 50 μg/actuation
- **DRUG:** Nasonex® Nasal Spray Suspnsn, 50 μg/actuation
- **DRUG:** Placebo Nasal Spray, 50 μL/actuation

## Key facts

- **NCT ID:** NCT02109185
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-10
- **Final completion:** 2013-11
- **Target enrollment:** 1307 (ACTUAL)
- **Last updated:** 2014-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109185, "A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02109185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*